// App-Quantinova.ai

283.0 : A study of pelareorep in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP).

Researchers

Presenter

  • Devalingam Mahalingam

Principal Investigators

  • Christos Fountzilas

  • Jennifer L. Moseley

  • Nicole Noronha

  • Karol Cheetham

  • Adrian Dzugalo

  • Gerard Nuovo

  • Andres Gutierrez

  • Sukeshi Patel Arora

Medical Centers

  • Northwestern University, Chicago, IL

  • Roswell Park Cancer Institute, Buffalo, NY

  • Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, San Antonio, TX

  • Oncolytics Biotech Inc., Calgary, AB, Canada

  • Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH

  • UT Health Science Center, San Antonio, TX

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Gemcitabine

  • Irinotecan

  • Pelareorep

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02620423

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved